Products for Research Use Only

Ritonavir-d6

CAT: 0804-HY-90001SSize: 1 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-90001SSize:1 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Ritonavir-d6 is the deuterium labeled Ritonavir. Ritonavir (ABT 538) is an inhibitor of HIV protease used to treat HIV infection and AIDS. Ritonavir is also a SARS-CoV 3CLpro inhibitor with an IC50 of 1.61 μM[1][2].
CAS Number
1616968-73-0
Product Name Alternative
ABT 538-d6; RTV-d6
UNSPSC
12352005
Hazard Statement
H302, H315, H319, H335
Target
Apoptosis; HIV; HIV Protease; SARS-CoV
Type
Isotope-Labeled Compounds
Related Pathways
Anti-infection; Apoptosis; Metabolic Enzyme/Protease
Applications
COVID-19-anti-virus
Field of Research
Infection
Purity
98.84
Solubility
10 mM in DMSO|DMF : ≥ 15mg/mL|DMSO : ≥ 15mg/mL|Ethanol : ≥ 5mg/mL
Smiles
O[C@@H](C[C@H](CC1=CC=CC=C1)NC([C@@H](NC(N(CC2=CSC(C(C([2H])([2H])[2H])C([2H])([2H])[2H])=N2)C)=O)C(C)C)=O)[C@H](CC3=CC=CC=C3)NC(OCC4=CN=CS4)=O
Molecular Formula
C37H42D6N6O5S2
Molecular Weight
726.98
Precautions
H302, H315, H319, H335
References & Citations
[1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53 (2) :211-216.|[2]Eagling VA, et al. Differential inhibition of cytochrome P450 isoforms by the protease inhibitors, ritonavir, saquinavir and indinavir. Br J Clin Pharmacol. 1997 Aug;44 (2) :190-4.|[3]Kumar GN, et al. Cytochrome P450-mediated metabolism of the HIV-1 protease inhibitor ritonavir (ABT-538) in human liver microsomes. J Pharmacol Exp Ther. 1996 Apr;277 (1) :423-31.|[4]Weichold FF, et al. HIV-1 protease inhibitor ritonavir modulates susceptibility to apoptosis of uninfected T cells. J Hum Virol. 1999 Sep-Oct;2 (5) :261-9.|[5]Drewe J, et al. HIV protease inhibitor ritonavir: a more potent inhibitor of P-glycoprotein than the cyclosporine analog SDZ PSC 833. Biochem Pharmacol. 1999 May 15;57 (10) :1147-52.|[6]Kumar GN, et al. Potent inhibition of the cytochrome P-450 3A-mediated human liver microsomal metabolism of a novel HIV protease inhibitor by ritonavir: A positive drug-drug interaction. Drug Metab Dispos. 1999 Aug;27 (8) :902-8.|[7]Qi Sun, et al. Bardoxolone and bardoxolone methyl, two Nrf2 activators in clinical trials, inhibit SARS-CoV-2 replication and its 3C-like protease. Signal Transduct Target Ther. 2021 May 29;6 (1) :212.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Isotope-Labeled Compounds
Clinical Information
No Development Reported